Managing CMC Risk For Complex Peptide And Nucleic Acid Therapeutics

As advanced therapeutic modalities move faster into the clinic, CMC has become one of the most critical risk areas in development. Peptides, oligonucleotides, mRNA-based therapies, and sophisticated delivery systems place growing demands on formulation, stability, and analytical understanding, particularly at the drug product level, where late-stage surprises can be costly.

TIDES USA 2026 in Boston brings together the global community working on peptide and nucleic acid therapeutics to address these CMC challenges head-on. This year’s discussions focus on how robust, science-driven CMC strategies can reduce late-stage risk, improve comparability across development phases, and enable faster, more confident decision-making.